Eli Lilly (LLY) Liabilities and Shareholders Equity (2016 - 2025)
Historic Liabilities and Shareholders Equity for Eli Lilly (LLY) over the last 17 years, with Q4 2025 value amounting to $112.5 billion.
- Eli Lilly's Liabilities and Shareholders Equity rose 4289.02% to $112.5 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $417.7 billion, marking a year-over-year increase of 4397.27%. This contributed to the annual value of $112.5 billion for FY2025, which is 4289.02% up from last year.
- Eli Lilly's Liabilities and Shareholders Equity amounted to $112.5 billion in Q4 2025, which was up 4289.02% from $114.9 billion recorded in Q3 2025.
- Over the past 5 years, Eli Lilly's Liabilities and Shareholders Equity peaked at $114.9 billion during Q3 2025, and registered a low of $46.8 billion during Q1 2021.
- For the 5-year period, Eli Lilly's Liabilities and Shareholders Equity averaged around $66.0 billion, with its median value being $56.4 billion (2023).
- As far as peak fluctuations go, Eli Lilly's Liabilities and Shareholders Equity plummeted by 155.91% in 2022, and later skyrocketed by 5201.71% in 2025.
- Eli Lilly's Liabilities and Shareholders Equity (Quarter) stood at $48.8 billion in 2021, then increased by 1.4% to $49.5 billion in 2022, then grew by 29.33% to $64.0 billion in 2023, then rose by 22.98% to $78.7 billion in 2024, then soared by 42.89% to $112.5 billion in 2025.
- Its Liabilities and Shareholders Equity stands at $112.5 billion for Q4 2025, versus $114.9 billion for Q3 2025 and $100.9 billion for Q2 2025.